| Chronic Kidney Diseases
Synjardy vs Xphozah
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Synjardy vs Xphozah 10 Mg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXphozah 10 Mg has a higher rate of injection site reactions vs Synjardy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xphozah 10 Mg but not Synjardy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Synjardy
Xphozah 10 Mg
At A Glance
Oral
Once or twice daily
SGLT2 inhibitor / biguanide
Oral
Twice daily
NHE3 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Congestive heart failure
- Chronic Kidney Diseases
- Chronic Kidney Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent SYNJARDY: empagliflozin 10 mg/day (may increase to 25 mg/day) plus metformin HCl up to 2,000 mg/day, taken orally twice daily with meals; SYNJARDY XR: once daily with morning meal; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Congestive heart failure, Chronic Kidney Diseases Empagliflozin 10 mg/day component as part of SYNJARDY or SYNJARDY XR, taken orally; not recommended if eGFR <45 mL/min/1.73 m2.
Chronic Kidney Diseases 30 mg orally twice daily, taken just prior to the first and last meals of the day; monitor serum phosphorus and adjust dosage as needed for gastrointestinal tolerability.
Contraindications
- Severe renal impairment (eGFR <30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, metformin HCl, or any excipient in SYNJARDY or SYNJARDY XR
- Age under 6 years due to risk of diarrhea and serious dehydration
- Known or suspected mechanical gastrointestinal obstruction
Adverse Reactions
Most common (>=5%) Hypoglycemia (with sulfonylurea), urinary tract infection, nasopharyngitis, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, vitamin B12 deficiency, lower limb amputation
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, rash, urticaria, cholestatic/hepatocellular liver injury
Most common (>=5%) Diarrhea (43-53% of patients)
Postmarketing Pruritis, rash, urticaria
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; metformin HCl is a biguanide antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
NHE3 inhibitor; tenapanor is a locally acting inhibitor of sodium/hydrogen exchanger 3 (NHE3), an antiporter on the apical surface of intestinal epithelium, whose inhibition reduces sodium absorption and decreases phosphate absorption by reducing paracellular phosphate permeability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Synjardy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Xphozah 10 Mg
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Synjardy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Xphozah 10 Mg
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Synjardy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Xphozah 10 Mg
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Synjardy.
No savings programs available for Xphozah 10 Mg.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SynjardyView full Synjardy profile
Xphozah 10 MgView full Xphozah 10 Mg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.